NPsVLCD SIGNED
Natural Product-Inspired Therapies for Leishmaniasis and Chagas Disease
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0NPsVLCD project word cloud
Explore the words cloud of the NPsVLCD project. It provides you a very rough idea of what is the project "NPsVLCD" about.
Project "NPsVLCD" data sheet
The following table provides information about the project.
| Coordinator |
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
Organization address contact info |
| Coordinator Country | United Kingdom [UK] |
| Total cost | 212˙933 € |
| EC max contribution | 212˙933 € (100%) |
| Programme |
1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility) |
| Code Call | H2020-MSCA-IF-2018 |
| Funding Scheme | MSCA-IF-EF-ST |
| Starting year | 2019 |
| Duration (year-month-day) | from 2019-08-01 to 2021-07-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD | UK (OXFORD) | coordinator | 212˙933.00 |
Map
Project objective
The development of new therapies for leishmaniases (which affeThe development of new therapies for visceral leishmaniasis (affects ~12 million people worldwide) and Chagas disease (~6-7 million people worldwide) is critically dependent on the identification of novel pharmacophores with new modes of action. Current treatments suffer from severe side effects, high cost, patient compliance issues, and emerging resistance; as such, new therapeutic leads are urgently required. Despite significant investment, limited progress has been made with research into new 'synthetic' drugs: no candidates are in clinical trials (although two compounds have recently progressed to preclinical evaluation for VL). In contrast, research into natural product-derived drugs has been largely ignored, despite their track record as frontline treatments for VL (amphotericin B) and the most prominent parasitic disease, malaria (artemisinin). In this project, we challenge this dogma through the exploration of a series of structurally-related alkaloid natural product families, where highly promising antiparasitic bioactivity has been observed in the few examples studied. The selection of these families is additionally based on their accessibility through concise, modular and convergent synthetic strategies, which facilitate modification. We couple this central focus of synthetic chemistry with collaborations to evaluate bioactivity (with expert parasitologist Prof Andre Tempone), and identify pharmacokinetic/dynamic limitations (with expert pharmacologist Prof Kevin Read), thereby informing analogue refinement and synthesis. This multidisciplinary approach will greatly enhance the impact of the synthetic chemistry work by providing 'real-time' feedback into compound design, enhancing project efficiency and progress. Our overarching, long term impact objective is to identify a new pharmacophore (and potentially new parasite target / mode of action) for the potential development of VL/CD therapies.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NPSVLCD" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "NPSVLCD" are provided by the European Opendata Portal: CORDIS opendata.